Earnings History Data for Diffusion Pharmaceuticals Inc. (DFFN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. is a biotechnology company. Its product pipeline includes Trans Sodium Crocetinate, Glioblastoma Program, Pancreatic Cancer Program and Brain Metastases Program. The Company is focused on cancer treatments, such as radiation therapy and chemotherapy in treatment-resistant solid tumors. Diffusion Pharmaceuticals Inc., formerly known as RestorGenex Corporation, is based in Charlottesville, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-11-2022	PM		DFFN	RestorGenex	9.00	-1.37	-2.06	0.00	Diffusion Pharmaceuticals GAAP EPS of -$1.37 beats by $0.69 [11/15/2022 4:04 AM]	5.75	0.76 (15.33%)	0.0	0.0 (0.00%)	4.64 - 24.50	21,318	10,000	0
Diffusion Pharmaceuticals GAAP EPS of -$1.37 beats by $0.69 [11/15/2022 4:04 AM] Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update [Nov-14-22 04:01PM] Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process [Nov-14-22 06:30AM]
12-05-2022	AH	After the close (May 12)	DFFN	RestorGenex	14.00	-2.22	-1.75	0.00	Diffusion Pharmaceuticals GAAP EPS of -$2.22 [5/12/2022 4:47 PM]	7.42	0.72 (10.66%)	7.30	0.59 (8.79%)	5.10 - 42.76	42,134	170,000	649
Diffusion Pharmaceuticals GAAP EPS of -$2.22 [5/12/2022 4:47 PM] Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update [May-12-22 04:05PM]
21-03-2022	PM	7:00 AM ET (Mar 21)	DFFN	RestorGenex	26.00	-0.04	-0.04	0.00	Diffusion Pharmaceuticals GAAP EPS of -$0.25 [3/21/2022 7:26 AM]	0.2501	-0.02 (-7.03%)	0.27	0.0 (0.37%)	0.20 - 1.07	705,188	815,001	11,881
Diffusion Pharmaceuticals GAAP EPS of -$0.25 [3/21/2022 7:26 AM] Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update [Mar-21-22 07:20AM]
10-11-2021	PM		DFFN	RestorGenex	47.00	-0.12	-0.04	0.00	Diffusion Pharmaceuticals EPS misses by $0.08 [11/10/2021 7:51 AM]	0.4301	-0.01 (-3.35%)	0.44	0.0 (-1.01%)	0.42 - 1.85	1,188,356	700,000	40,110
Diffusion Pharmaceuticals EPS misses by $0.08 [11/10/2021 7:51 AM] Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update [Nov-10-21 07:02AM]
11-08-2021	PM		DFFN	Restorgenex Corp.	56.00	-0.04	-0.05	0.00	Diffusion Pharmaceuticals reports Q2 results [8/11/2021 7:47 AM]	0.5374	-0.03 (-5.57%)	0.59	0.02 (2.93%)	0.51 - 1.85	2,249,661	1,220,000	85,826
Diffusion provides COVID-19 study data timeline update, sees cash runway through 2023 [8/11/2021 8:05 AM] Diffusion Pharmaceuticals reports Q2 results [8/11/2021 7:47 AM] Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update [Aug-11-21 07:32AM]
10-05-2021	PM		DFFN	Diffusion Pharmaceuticals Inc.	69.35	-0.06	-0.05	-0.07	Diffusion Pharmaceuticals EPS misses by $0.02 [5/10/2021 7:54 AM]	0.7693	0.09 (12.75%)	0.71	0.03 (4.00%)	0.61 - 1.85	3,554,572	1,150,000	499,639
Diffusion Pharmaceuticals EPS misses by $0.02 [5/10/2021 7:54 AM] Diffusion Pharma (DFFN) gains 17% on final TSC data in hospitalized COVID-19 patients [5/10/2021 8:05 AM] Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update [May-10-21 07:05AM] Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients [May-10-21 07:50AM] Diffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients [May-10-21 10:23AM]